🩷
ClarityPSA
Know your numbers. Own your health.
Understand your prostate cancer screening results — in plain language, backed by peer-reviewed research.
📊
Track PSA, 4K Score, 4K Density, EPI, PHI and MRI findings in one place
🔒
No data stored or uploaded. Everything stays on your device only.
📚
Evidence-based. Every insight linked to PubMed-indexed research.
🏥
Find fellowship-trained urologists near you.
Tell us about yourself
Personalizes the research context shown to you. Nothing leaves your device.
Basic profile
Ageyears
Race / ethnicity
Race and age affect prostate cancer incidence, aggressiveness, and screening recommendations. This context will be reflected in your personalized results.
About ClarityPSA
Our mission
ClarityPSA was built to make prostate cancer screening easier to understand. Navigating PSA values, MRI reports, and biomarker results can be overwhelming — our goal is to provide patients with up-to-date education, published literature, and current AUA screening guidelines in one place, so they can arrive at their next appointment informed and ready to have better conversations with their care team.
TG
Timothy Guerard
Founder · Aspiring Urologic Oncology Surgeon-Scientist
Timothy is a first-year medical student aspiring to be a future Urologic Oncology Surgeon-Scientist. He led initial research into the 4K Density concept during his time as a research coordinator at the Desai Sethi Urology Institute prior to medical school.

His research has been published first-author in Nature's Prostate Cancer and Prostatic Diseases and in the Journal of Urology, with additional contributions across multiple peer-reviewed publications in urologic oncology. He has presented original research at the AUA, SUO, WSAUA, and SMSNA.
Research foundation
Nature · Prostate Cancer & Prostatic Diseases · 2025 · First Author
4K Density: Adjusting the 4Kscore for prostate volume to improve risk stratification of clinically significant prostate cancer
Guerard T, Porto JG, Fekete T, et al. · n=1,983 · University of Miami
PubMed: 41107473 →
Journal of Urology · Oct 2025 · Contributing Author
Can Genomic Classifiers in Biopsy Cores With Grade Group 1 Cancer Predict Higher-Grade Disease Elsewhere in the Prostate? Results From the Prospective Miami Active Surveillance Trial
Freitas PFS, Khandekar A, Porto JG, Williams AD, ..., Guerard T, ..., Punnen S.
PubMed: 40540647 →
Healthcare Technology Letters · Nov 2025 · Contributing Author
Augmented Reality in Outpatient Care: A Narrative Review
Khandekar A, Shah A, Miranda LAE, ..., Guerard T, Parekh DJ.
PubMed: 41287787 →
Urologic Oncology · Nov 2024 · Contributing Author
Molecular and Diffusion Features for Identification of Clinically Significant Prostate Cancer in PI-RADS 3 Lesions
Ajami T, Han S, Porto JG, ..., Guerard T, ..., Punnen S.
PubMed: 38971674 →
ClarityPSA is an independent educational tool.
It is not affiliated with OPKO Health, ExoDx, or any biomarker company.
© 2025
🩷

ClarityPSA

Personalized prostate cancer screening companion

My biomarker values
Step 1 — PSA & Prostate Volume
PSAng/mL
Prostate volume (from MRI)cc
PSA densityng/mL/cc
Step 2 — 4K Score
4K Score%
4K Densityscore/cc
Step 3 — Other Biomarkers (enter any you have)
EPI Score (ExoDx)0–100
PHI Scoreindex
Step 4 — MRI Finding
PI-RADS 1–2
PI-RADS 3
PI-RADS 4
PI-RADS 5
Here is what current research suggests
Educational context only, based on PubMed-indexed research. Does not replace your urologist's clinical judgment. Bring these results to your next appointment and ask your doctor what they mean for you specifically.
Understanding your MRI report

Prostate MRIs are scored with the PI-RADS system (1–5). Here is what each score means in plain language — and what the published evidence says about next steps.

PI-RADS 1 or 2 — Very low / Low suspicion
Your MRI did not find anything concerning. Clinically significant prostate cancer is unlikely based on imaging alone. Your doctor may recommend continued PSA monitoring without biopsy.
PI-RADS 3 — Intermediate / Indeterminate
The "grey zone." The MRI found something equivocal. This is where secondary biomarkers like the 4K Score add the most clinical value — a high score may support biopsy while a low score may support watchful waiting. In a study of 2,538 men, biopsy rates in PI-RADS 3 patients differed by 34 percentage points based on 4K Score alone.
PI-RADS 4 or 5 — High / Very high suspicion
The MRI found a lesion with high likelihood of being clinically significant prostate cancer. Current AUA and EAU guidelines recommend biopsy in most men with these findings. Published data show 6–12x higher odds of proceeding to biopsy vs. a negative MRI.
Before your appointment — checklist
• Write down your PI-RADS score and lesion size from your report
• Note whether your report mentions the transition zone or peripheral zone
Bring the CD or disc of your MRI images if they cannot be sent electronically — your urologist needs the actual scans, not just the text report
• Ask for a copy of the full written radiology report
• Write down 2–3 questions you want to ask your doctor before you go in
PSA log
Log a new PSA value
Date
PSA valueng/mL
Note (optional)
No PSA values logged yet.
Add your first entry above to start tracking.
Evidence-based lifestyle guidance
🏃

Aerobic exercise

150+ min/week associated with slower PSA progression and improved quality of life on active surveillance.

 
🥦

Mediterranean diet

Associated with lower PSA progression rates and reduced risk of clinically significant prostate cancer.

 
🧘

Pelvic floor rehab

Pre- and post-operative pelvic floor training significantly reduces urinary incontinence duration after RALP.

 
Find a urologist near you

Enter your zip code to search for fellowship-trained urologists in your area via the AUA's verified physician directory.

💡 Tip: When searching, look for board-certified urologists with fellowship training in urologic oncology. Check that they have experience with prostate MRI-guided biopsy and the biomarker tests your doctor ordered.
Featured academic specialists

Dr. Sanoj Punnen, MD MAS MBA

Professor of Urologic Oncology · Desai Sethi Urology Institute, University of Miami

Prostate cancer 4K Score & MRI NCI-funded PI
⭐ 4.9
Miami, FL
Profile →

Dr. Mark L. Gonzalgo, MD PhD MBA

Chair, Dept. of Urology · Desai Sethi Urology Institute, University of Miami

Robotic surgery AUA Education Chair
⭐ 4.9
Miami, FL
Profile →

Dr. Dipen J. Parekh, MD

Founding Director, Desai Sethi Urology Institute · CEO, UHealth

Robotic oncology AUA Gold Cystoscope
⭐ 4.9
Miami, FL
Profile →

Dr. Chad R. Ritch, MD MBA

Associate Professor of Urologic Oncology · Desai Sethi Urology Institute

Bladder & prostate cancer AUA Leadership 2025–26
⭐ 4.8
Miami, FL
Profile →

Dr. Eric H. Kim, MD

Urologic Oncology · University of Nevada, Reno School of Medicine

Prostate cancer MRI-guided biopsy
⭐ 4.8
Reno, NV
Profile →

Publicly listed academic urologists. Always verify availability and insurance directly with the institution.

Our mission
ClarityPSA was built to make prostate cancer screening easier to understand. Our goal is to provide patients with up-to-date education, published literature, and current AUA screening guidelines in one place, so they can arrive at their next appointment informed and ready to have better conversations with their care team.
TG
Timothy Guerard
Founder · Aspiring Urologic Oncology Surgeon-Scientist
Timothy is a first-year medical student aspiring to be a future Urologic Oncology Surgeon-Scientist. He led initial research into the 4K Density concept during his time as a research coordinator at the Desai Sethi Urology Institute prior to medical school. His work has been published first-author in Nature's Prostate Cancer and Prostatic Diseases, with additional contributions across peer-reviewed publications. He has presented original research at the AUA, SUO, WSAUA, and SMSNA.
Published research behind this app
Nature · PCAN · 2025 · First Author
4K Density: Adjusting the 4Kscore for prostate volume to improve risk stratification
Guerard T, Porto JG, Fekete T, et al. · n=1,983 · University of Miami
PubMed 41107473 →
Journal of Urology · Oct 2025 · Contributing Author
Genomic Classifiers in Grade Group 1 Biopsy Cores — Miami Active Surveillance Trial
Freitas PFS, Khandekar A, ..., Guerard T, ..., Punnen S. · J Urol 2025;214(4):383–392
PubMed 40540647 →
Urologic Oncology · Nov 2024 · Contributing Author
Molecular and Diffusion Features for csPCa Identification in PI-RADS 3 Lesions
Ajami T, Han S, Porto JG, ..., Guerard T, ..., Punnen S. · Urol Oncol 2024;42(11)
PubMed 38971674 →
Key supporting reference · PI-RADS & MRI
Negative predictive value of mpMRI — systematic review & meta-analysis
Sathianathen NJ et al., Eur Urol 2020;78(3):402–414
PubMed 32396916 →
ClarityPSA is an independent educational tool.
Not affiliated with any biomarker company.
© 2025 Timothy Guerard · claritypsa.org